Novel antifungal shows early promise against Candida auris

  11 April 2019

Biotechnology company Scynexis, Inc., is reporting early but promising results from a phase 3 trial of a novel drug for treating invasive Candida aurisinfections.

The company will present the results from the first two case studies in the CARES trial at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam. The single-arm trial is evaluating the efficacy and safety of oral ibrexafungerp in patients with candidiasis caused by C auris, a multidrug-resistant fungus that has triggered deadly outbreaks in healthcare facilities around the world, with mortality rates as high as 60%.

Further reading: CIDRAP
Healthy Patients   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!